[Form 4] Iridex Corp Insider Trading Activity

Rhea-AI Filing Summary

Iridex Corp (IRIX) insider purchase reported. Romeo R. Dizon, listed as Chief Financial Officer and reporting person, acquired a total of 1,500 shares on 08/18/2025 in two transactions: 460 shares at $1.19 and 1,040 shares at $1.1723. After these purchases he is shown as beneficially owning 40,745 shares.

Positive

• Reporting person executed purchases (net increase of 1,500 shares)
• Purchases disclosed promptly on Form 4 with post-transaction ownership of 40,745 shares

Negative

• None.

Insights

Financial Analyst

TL;DR: Company CFO bought 1,500 IRIX shares at roughly $1.18, a modest insider purchase.

The transactions are small in absolute dollar terms and reflect an insider purchase rather than a sale, which can signal confidence by management in the companys prospects. No derivative transactions or dispositions are reported. The filings show post-transaction beneficial ownership of 40,745 shares, which provides context on the insiders stake size.

Corporate Governance Expert

TL;DR: Routine Form 4 reporting of insider purchases by the CFO; no governance red flags evident.

The Form 4 is signed by an attorney-in-fact and discloses two purchase entries executed on the same date. The filing indicates individual reporting and does not show amendments or complex arrangements. From a governance perspective, the disclosure appears complete and timely based on the information provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dizon Romeo R

(Last) (First) (Middle)

1212 TERRA BELLA AVENUE

(Street)

MOUNTAIN VIEW CA 94043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		P		460	A	$1.19	39,705	D
Common Stock	08/18/2025		P		1,040	A	$1.1723	40,745	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Nilo De Castro, Attorney-in-fact for Romeo Dizon	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for IRIX on this Form 4?

The Form 4 reports that Romeo R. Dizon purchased 460 shares at $1.19 and 1,040 shares at $1.1723 on 08/18/2025, totaling 1,500 shares.

Who filed the Form 4 for IRIDEX (IRIX)?

The filing lists Romeo R. Dizon, identified as the company's Chief Financial Officer, as the reporting person; the form is signed by an attorney-in-fact, Nilo De Castro.

How many IRIX shares does the reporting person own after the transactions?

Following the reported purchases, the Form 4 shows the reporting person beneficially owns 40,745 shares.

Were any derivative securities reported in this Form 4 for IRIX?

No derivative securities are reported; Table II (derivatives) contains no entries in the provided content.

When were the transactions executed per the Form 4?

Both non-derivative purchase transactions are dated 08/18/2025 per the filing.